Back to Press Releases Accu

Contact: Lori LeRoy
Roche Diagnostics

Accu-Chek® Multiclix Lancet Device Provides Patients With New Option For Testing

Preloaded, 6-lancet drum eliminates handling of individual lancets

San Diego, June 11, 2005 - Today at the American Diabetes Association Scientific Sessions in San Diego, California, Indianapolis-based Roche Diagnostics, a leader in diabetes care products and services, exhibited its new Accu-Chek® Multiclix lancet device. The Accu-Chek Multiclix lancet device is the first lancing device with a patented, preloaded, 6-lancet drum which provides more convenience and improves safety by reducing accidental finger-sticks of handling individual lancets. With no lancets to see or handle, a patented cam-driven design, 11 different depth settings and alternate site testing, the Accu-Chek Multiclix system is the least painful testing option1.

The Accu-Chek Multiclix lancet device, with its integrated lancet drum, takes the effort out of lancet changing and disposal. Its patented cam-driven, linear lancet guidance system also results in less skin tearing and helps make sampling the least painful.1 The Accu-Chek Multiclix system includes thin, specially sharpened (30g) lancets that gently penetrate the skin and give users the choice of 11 penetration depth settings to suit their individual skin type and the volume of blood required. It also offers a clear testing cap for alternate site testing options.

In a consumer study of more than 120 participants, the Accu-Chek Multiclix lancet device was least painful, easier to use, and quicker than the leading competitive lancing systems.1 In fact, more than 90 percent of the participants ranked the Accu-Chek Multiclix lancet device as less painful than their current device (fingertip testing).1

Accu-Chek Multiclix lancet device will be available in the third quarter and will be available as an individual kit. It will also be packaged with the Accu-Chek Aviva blood glucose system.

About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-intensive healthcare groups. Its core businesses are pharmaceuticals and diagnostics. As a supplier of innovative products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in Diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004, the Pharmaceuticals Division generated 21.7 billion Swiss francs in prescription drug sales, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division, with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. Roche Diagnostics' North American headquarters is located in Indianapolis, Ind. ( For further information, please visit our websites and

Roche's Diagnostics Division, the world leader in diagnostics with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.

Accu-Chek brand is a pioneer in the development of blood glucose monitoring systems and a global leader for comprehensive diabetes care. This means offering people with diabetes innovative products and services ranging from blood glucose monitoring through data management to insulin delivery. For 30 years, the Accu-Chek brand has been committed to making life easier for people with diabetes and healthcare professionals with innovative products and services which make diabetes management easier, more efficient and cost effective. The Accu-Chek family of products encompasses blood glucose meters, lancing and data management systems, such as the Accu-Chek Compact, Accu-Chek Advantage and Accu-Chek Softclix systems (

1Koubek, R.J. (2005). Glucose Monitoring System Design Reduces Barriers to Testing, Accu-Chek Aviva System and Accu-Chek Multiclix lancet device Human Factors White Paper.



  Multiclix box
The Multiclix box. Click for a larger image.

Multiclix lancet
The Multiclix lancet between a BD 33 gauge and 30 gauge lancet. Each Multiclix cartridge holds six lancets. Click for a larger image.

  Back to Press Releases Return to the Top of This Page

Last Updated: (none)
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.